486 related articles for article (PubMed ID: 31548347)
21. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
22. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
24. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
[TBL] [Abstract][Full Text] [Related]
25.
Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
[TBL] [Abstract][Full Text] [Related]
26. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
27. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
28. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Riess JW; Frankel P; Shackelford D; Dunphy M; Badawi RD; Nardo L; Cherry SR; Lanza I; Reid J; Gonsalves WI; Kunos C; Gandara DR; Lara PN; Newman E; Paik PK
Clin Lung Cancer; 2021 Jan; 22(1):67-70. PubMed ID: 33229301
[TBL] [Abstract][Full Text] [Related]
29. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
30. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
31. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
Dempke WCM; Reck M
Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
[TBL] [Abstract][Full Text] [Related]
32. [Keap1 expression for predicting the chemoresistance and prognosis of advanced non-small cell lung cancer].
Cao B; Zhu X; Chen S; Xiao Y; Liang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):591-6. PubMed ID: 23075683
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
34. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
35. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
36. A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
Hijazo-Pechero S; Muñoz-Pinedo C; Nadal E
J Thorac Oncol; 2023 Nov; 18(11):1431-1433. PubMed ID: 37879763
[No Abstract] [Full Text] [Related]
37. KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
Zhang C; Zhang C; Li J; Wang H
J Thorac Oncol; 2020 Jun; 15(6):e85-e86. PubMed ID: 32471565
[No Abstract] [Full Text] [Related]
38. KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials.
Zhu H; Xie D; Yu Y; Yao L; Xu B; Huang L; Wu S; Li F; Zheng Y; Liu X; Xie W; Huang M; Li H; Zheng S; Zhang D; Qiao G; Chan LWC; Zhou H
Front Oncol; 2021; 11():659200. PubMed ID: 34381706
[TBL] [Abstract][Full Text] [Related]
39. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
40. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
